The deal will see contract development and manufacturing organisation (CDMO) AMRI initially provide cGMP manufacture and analytical support for the registration of five of Genovi’s product candidates.
Last week AMRI shelled out $60m (€50m) for two Aptuit facilities – an aseptic manufacturing plant in Glasgow, UK, and an analytical chemistry services site in West Lafayette, Indiana – but spokesperson Gina Rothe said this announcement is unrelated to the acquisition.
“Although the two announcements are unrelated, we are excited about the ability to extend the benefits of our integrated service offering to new and existing customers for development, analytical services and commercial scale manufacturing of strategic and complex injectable products,” she told Outsourcing-Pharma.com.
Financial details were not disclosed, but AMRI will be reimbursed for technology transfer activities, analytical development and manufacture of regulatory submission batches, as well as receiving regulatory milestone payments. Under the terms of the deal, AMRI will supply Genovi with the products following regulatory approval.